Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain
Por:
Notario, J, Deza, G, Vilarrasa, E, Valenti, F, Munoz, C, Mollet, J, Rocamora, V, Carrascosa, JM, del Alcazar, E, Alsina, M, Vidal, D, Puig, L, Lopez-Ferrer, A, Riera, J, Gallardo, F, Ferran, M
Publicada:
4 jul 2019
Resumen:
Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO) have been demonstrated in randomized clinical trials (RCTs). However, data regarding its efficacy and safety in real-life settings are scarce. Objectives: To evaluate the efficacy and safety of secukinumab in clinical practice in patients with PsO attending 10 dermatology centers in Spain. Methods: Data from 136 patients consecutively treated with secukinumab for at least 52 weeks were collected in a retrospective observational study. Results: After 52 weeks of treatment, 69% and 46% of patients achieved a PASI-75, PASI-90, respectively. PASI-score <= 5 was achieved in 83% of patients, PASI-score <= 3 in 73% and PASI-score <= 1 in 47%. Response rates were found significantly lower in patients with obesity and non-naive to biologics (p < .05). The most common adverse event (AE) was candidiasis (5/136). Thirty-six patients (26.5%) discontinued treatment by week 52 due to lack or loss of response (n = 29), AEs (n = 2) or other causes (n = 5). Conclusion: These findings complement the efficacy and safety profiles of secukinumab in PsO outlined in RCTs. The effectiveness in clinical practice may be lower in patients with a BMI >= 30 and those previously treated with other biologic agents.
Filiaciones:
Notario, J:
Hosp Univ Bellvitge, Dept Dermatol, Feixa Llarga S-N, Lhospitalet De Llobregat 08907, Spain
Deza, G:
Hosp del Mar, Inst Mar Invest Med, Dept Dermatol, Barcelona, Spain
Vilarrasa, E:
Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
Valenti, F:
Hosp Univ Bellvitge, Dept Dermatol, Feixa Llarga S-N, Lhospitalet De Llobregat 08907, Spain
Munoz, C:
Hosp Granollers, Dept Dermatol, Granollers, Spain
Mollet, J:
Hosp Valle De Hebron, Dept Dermatol, Barcelona, Spain
Rocamora, V:
Hosp Manacor, Dept Dermatol, Manacor, Spain
Carrascosa, JM:
Hosp Badalona Germans Trias & Pujol, Dept Dermatol, Badalona, Spain
del Alcazar, E:
Hosp Sagrat Cor, Dept Dermatol, Barcelona, Spain
Alsina, M:
Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain
Vidal, D:
Hosp Moisses Broggi, Dept Dermatol, St Joan Despi, Spain
Puig, L:
Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
Lopez-Ferrer, A:
Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
Riera, J:
Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain
Gallardo, F:
Hosp del Mar, Inst Mar Invest Med, Dept Dermatol, Barcelona, Spain
Ferran, M:
Hosp del Mar, Inst Mar Invest Med, Dept Dermatol, Barcelona, Spain
|